• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多囊卵巢综合征年轻女性2型糖尿病风险评估

Assessment of Type 2 Diabetes Risk in Young Women with Polycystic Ovary Syndrome.

作者信息

Livadas Sarantis, Paparodis Rodis, Anagnostis Panagiotis, Gambineri Alessandra, Bjekić-Macut Jelica, Petrović Tijana, Yildiz Bulent O, Micić Dragan, Mastorakos George, Macut Djuro

机构信息

Endocrine Unit, Athens Medical Centre, 65403 Athens, Greece.

Center for Diabetes and Endocrine Research, University of Toledo College of Medicine and Life Sciences, Toledo, OH 43614, USA.

出版信息

Diagnostics (Basel). 2023 Jun 14;13(12):2067. doi: 10.3390/diagnostics13122067.

DOI:10.3390/diagnostics13122067
PMID:37370962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10297688/
Abstract

Women with polycystic ovary syndrome (PCOS) are at increased risk for dysglycemia and type 2 diabetes compared to healthy BMI-matched women of reproductive age: robust evidence exists supporting this notion. The presence of altered glycemic status in young women with the syndrome presents a distinct challenge for the clinician for several reasons. Firstly, the reported incidence of this disorder varies among the limited available studies. Furthermore, there is a lack of consensus on the best screening method, which women to screen, at what frequency, and which strategies need to be implemented to reduce the above risk. We provide data regarding the prevalence of dysglycemia in young women suffering from PCOS and the pathophysiological mechanisms underlying the disorder. In addition, we present evidence suggesting universal screening with the oral glucose tolerance test in young women with the syndrome, irrespective of age or BMI status, to identify and manage glycemic abnormalities in a timely manner. Regarding follow-up, oral glucose testing should be carried out at regular intervals if there are initial abnormal findings or predisposing factors. Finally, the efficacy of a well-balanced diet in conjunction with regular exercise and the use of non-pharmacologic agents in this specific population is discussed.

摘要

与健康的、体重指数(BMI)匹配的育龄女性相比,患有多囊卵巢综合征(PCOS)的女性发生血糖异常和2型糖尿病的风险更高:有充分的证据支持这一观点。患有该综合征的年轻女性出现血糖状态改变给临床医生带来了独特的挑战,原因有几个。首先,在现有的有限研究中,该疾病的报告发病率各不相同。此外,对于最佳筛查方法、筛查哪些女性、筛查频率以及需要实施哪些策略来降低上述风险,目前尚无共识。我们提供了关于患有PCOS的年轻女性血糖异常患病率的数据以及该疾病的病理生理机制。此外,我们还提出证据表明,对于患有该综合征的年轻女性,无论年龄或BMI状况如何,都应通过口服葡萄糖耐量试验进行普遍筛查,以便及时发现和管理血糖异常。关于随访,如果最初有异常发现或易感因素,应定期进行口服葡萄糖测试。最后,讨论了均衡饮食结合规律运动以及在这一特定人群中使用非药物治疗的效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e4b/10297688/8209c6a8ab84/diagnostics-13-02067-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e4b/10297688/8209c6a8ab84/diagnostics-13-02067-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e4b/10297688/8209c6a8ab84/diagnostics-13-02067-g001.jpg

相似文献

1
Assessment of Type 2 Diabetes Risk in Young Women with Polycystic Ovary Syndrome.多囊卵巢综合征年轻女性2型糖尿病风险评估
Diagnostics (Basel). 2023 Jun 14;13(12):2067. doi: 10.3390/diagnostics13122067.
2
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME - PART 2.美国临床内分泌医师协会、美国内分泌学会以及雄激素过多与多囊卵巢综合征协会疾病状态临床综述:多囊卵巢综合征评估与治疗最佳实践指南 - 第2部分。
Endocr Pract. 2015 Dec;21(12):1415-26. doi: 10.4158/EP15748.DSCPT2.
3
Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome.多囊卵巢综合征患者中月经功能障碍严重程度与高胰岛素血症和糖代谢异常的关系。
Hum Reprod. 2022 Mar 1;37(3):553-564. doi: 10.1093/humrep/deac001.
4
Polycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review.多囊卵巢综合征与2型糖尿病:最新综述
World J Diabetes. 2022 Jan 15;13(1):5-26. doi: 10.4239/wjd.v13.i1.5.
5
Comprehensive Evaluation of Type 2 Diabetes and Cardiovascular Disease Risk Profiles in Reproductive-Age Women with Polycystic Ovary Syndrome: A Large Canadian Cohort.多囊卵巢综合征育龄妇女2型糖尿病和心血管疾病风险概况的综合评估:一项大型加拿大队列研究
J Obstet Gynaecol Can. 2019 Oct;41(10):1453-1460. doi: 10.1016/j.jogc.2018.11.026. Epub 2019 Feb 1.
6
Assessment of impaired glucose tolerance prevalence with hemoglobin A₁c and oral glucose tolerance test in 252 Turkish women with polycystic ovary syndrome: a prospective, controlled study.采用糖化血红蛋白和口服葡萄糖耐量试验评估 252 例多囊卵巢综合征土耳其女性的葡萄糖耐量受损患病率:一项前瞻性、对照研究。
Hum Reprod. 2013 Apr;28(4):1062-8. doi: 10.1093/humrep/det002. Epub 2013 Jan 18.
7
Can dysglycemia in OGTT be predicted by baseline parameters in patients with PCOS?多囊卵巢综合征患者的口服葡萄糖耐量试验中的血糖异常能否通过基线参数预测?
Endocr Connect. 2022 Apr 22;11(4):e210358. doi: 10.1530/EC-21-0358.
8
Assessment of glucose metabolism in polycystic ovary syndrome: HbA1c or fasting glucose compared with the oral glucose tolerance test as a screening method.多囊卵巢综合征患者糖代谢评估:糖化血红蛋白或空腹血糖与口服葡萄糖耐量试验作为筛查方法的比较。
Hum Reprod. 2013 Sep;28(9):2537-44. doi: 10.1093/humrep/det255. Epub 2013 Jun 11.
9
Polycystic Ovary Syndrome, Combined Oral Contraceptives, and the Risk of Dysglycemia: A Population-Based Cohort Study With a Nested Pharmacoepidemiological Case-Control Study.多囊卵巢综合征、复方口服避孕药与血糖异常风险:一项基于人群的队列研究及巢式药物流行病学病例对照研究。
Diabetes Care. 2021 Dec;44(12):2758-2766. doi: 10.2337/dc21-0437. Epub 2021 Oct 14.
10
The role of a pulse-based diet on infertility measures and metabolic syndrome risk: protocol of a randomized clinical trial in women with polycystic ovary syndrome.基于脉搏的饮食对不孕症指标和代谢综合征风险的作用:一项针对多囊卵巢综合征女性的随机临床试验方案
BMC Nutr. 2017 Mar 7;3:23. doi: 10.1186/s40795-017-0142-6. eCollection 2017.

引用本文的文献

1
Alteration of the N-methyladenosine methylation landscape in a mouse model of polycystic ovary syndrome.多囊卵巢综合征小鼠模型中 N6-甲基腺苷甲基化修饰图谱的改变。
J Ovarian Res. 2023 Aug 8;16(1):157. doi: 10.1186/s13048-023-01246-7.

本文引用的文献

1
Alpha-Lipoic Acid and Glucose Metabolism: A Comprehensive Update on Biochemical and Therapeutic Features.α-硫辛酸与糖代谢:生化与治疗特征的全面更新。
Nutrients. 2022 Dec 21;15(1):18. doi: 10.3390/nu15010018.
2
PCOS Physiopathology and Vitamin D Deficiency: Biological Insights and Perspectives for Treatment.多囊卵巢综合征的病理生理学与维生素D缺乏:生物学见解及治疗前景
J Clin Med. 2022 Aug 2;11(15):4509. doi: 10.3390/jcm11154509.
3
Reconsidering the Polycystic Ovary Syndrome (PCOS).重新审视多囊卵巢综合征(PCOS)。
Biomedicines. 2022 Jun 25;10(7):1505. doi: 10.3390/biomedicines10071505.
4
Can dysglycemia in OGTT be predicted by baseline parameters in patients with PCOS?多囊卵巢综合征患者的口服葡萄糖耐量试验中的血糖异常能否通过基线参数预测?
Endocr Connect. 2022 Apr 22;11(4):e210358. doi: 10.1530/EC-21-0358.
5
Prevalence of Polycystic Ovary Syndrome in Patients With Pediatric Type 2 Diabetes: A Systematic Review and Meta-analysis.多囊卵巢综合征在儿科 2 型糖尿病患者中的患病率:系统评价和荟萃分析。
JAMA Netw Open. 2022 Feb 1;5(2):e2147454. doi: 10.1001/jamanetworkopen.2021.47454.
6
Cardiovascular Risk Factors and Subclinical Atherosclerosis in Greek Adolescents with Polycystic Ovary Syndrome: Its Relationship with Body Mass Index.希腊多囊卵巢综合征青少年的心血管危险因素与亚临床动脉粥样硬化:其与体重指数的关系
Children (Basel). 2021 Dec 22;9(1):4. doi: 10.3390/children9010004.
7
Risk of type 2 diabetes mellitus in polycystic ovary syndrome is associated with obesity: a meta-analysis of observational studies.多囊卵巢综合征患者发生 2 型糖尿病的风险与肥胖有关:一项观察性研究的荟萃分析。
Endocrine. 2021 Nov;74(2):245-253. doi: 10.1007/s12020-021-02801-2. Epub 2021 Jun 26.
8
Targeting Elevated GnRH Pulsatility to Treat Polycystic Ovary Syndrome.针对GnRH脉冲频率升高治疗多囊卵巢综合征。
J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4275-e4277. doi: 10.1210/clinem/dgab422.
9
Higher risk of type 2 diabetes in women with hyperandrogenic polycystic ovary syndrome.患有高雄激素多囊卵巢综合征的女性患 2 型糖尿病的风险更高。
Fertil Steril. 2021 Sep;116(3):862-871. doi: 10.1016/j.fertnstert.2021.04.018. Epub 2021 May 28.
10
Development of type 2 diabetes in adolescent girls with polycystic ovary syndrome and obesity.多囊卵巢综合征和肥胖的青春期少女 2 型糖尿病的发生。
Pediatr Diabetes. 2021 Aug;22(5):699-706. doi: 10.1111/pedi.13206. Epub 2021 Apr 27.